Tue, Mar 3, 2015, 2:53 AM EST - U.S. Markets open in 6 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

csr1223 5 posts  |  Last Activity: Feb 19, 2015 9:43 AM Member since: Feb 23, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What's the next BLUE?

    by bint244 Feb 18, 2015 4:19 PM
    csr1223 csr1223 Feb 19, 2015 9:43 AM Flag

    SGMO, CUR, NVAX

  • Reply to

    March $2.50 Call Options

    by jemer1234 Feb 18, 2015 8:14 PM
    csr1223 csr1223 Feb 18, 2015 10:46 PM Flag

    Agree with Brownlady, BCLI has not published any of their preclinical work. Seems very shady.

  • The cytotoxic T lymphocyte antigen 4 (CTLA 4) blocking antibody ipilimumab results in durable responses in metastatic melanoma, though therapeutic benefit has been limited to a fraction of patients. This calls for identification of resistance mechanisms and development of combinatorial strategies. Here, we examine the inhibitory role of indoleamine 2,3 dioxygenase (IDO) on the antitumor efficacy of CTLA 4 blockade. In IDO knockout mice treated with anti CTLA 4 antibody, we demonstrate a striking delay in B16 melanoma tumor growth and increased overall survival when compared with wild-type mice. This was also observed with antibodies targeting PD 1 PD L1 and GITR. To highlight the therapeutic relevance of these findings, we show that CTLA 4 blockade strongly synergizes with IDO inhibitors to mediate rejection of both IDO-expressing and nonexpressing poorly immunogenic tumors, emphasizing the importance of the inhibitory role of both tumor- and host-derived IDO. This effect was T cell dependent, leading to enhanced infiltration of tumor-specific effector T cells and a marked increase in the effector-to-regulatory T cell ratios in the tumors. Overall, these data demonstrate the immunosuppressive role of IDO in the context of immunotherapies targeting immune checkpoints and provide a strong incentive to clinically explore combination therapies using IDO inhibitors irrespective of IDO expression by the tumor cells.
    Paper's Author's are from nice group of Cancer Research Institutes:
    Rikke B. Holmgaard1,2, Dmitriy Zamarin1,2,3, David H. Munn4, Jedd D. Wolchok2,3,5,6, and James P. Allison1,7
    Author Affiliations
    1Howard Hughes Med Inst, Dept Immunology, Memorial Sloan Kettering Cancer Ctr
    2Ludwig Collaborative Rsch Lab, Immunology, Sloan Kettering Inst for Cancer Rsch
    3Dept Med, Memorial Sloan Kettering Cancer Center
    4Cancer Center, Georgia Regents Univ
    5Weill Cornell Medical College
    6Ludwig Inst Cancer Rsch, NY
    7Univ of Texas, MD Anderson Cancer Center, Dept Immunology

  • csr1223 csr1223 Jan 26, 2015 1:32 PM Flag

    FTGrad,

    I don't think there is much significance to the guest editor title as all of their planned Qtrly publications include "guest editors".

    csr

  • Dr. Eva Feldman is scheduled to publish in this journal in April of this year.

    April 2015 - Therapeutic Advances in Neuromuscular Diseases
    Guest Editors: Eva Feldman (University of Michigan) and Stacey Sakowski (University of Michigan)

    asentdotorg/neurotherapeuticsandreg/journaltopics/neurotherapeutic-topics#Topic2015

    Sentiment: Strong Buy

NWBO
7.23-0.14(-1.90%)Mar 2 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.